Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
By P. Fenaux, G. Mufti, E. Hellström-Lindberg, V. Santini, N. Gattermann, U. Germing, G. Sanz, A. List, S. Gore, J. Seymour and 6 more. Journal of Clinical Oncology, 2010
940 citations recorded by the source corpus.
Subfields: Genetics, Hematology
View Paper: https://www.semanticscholar.org/paper/d3b22db2593452d05be2a2030cf5325332f46991
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Hematology
Citations in the corpus
- Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. (2012, methodology): “A retrospective subanalysis of data from a phase III trial in patients with MDS evaluated survival with azacitidine (n 55) versus conventional care (best SC, low-dose cytarabine, or intensive chemotherapy; n 58).16,17 The study population, which was originally classified as having refractory anemia ”
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. (2017, background): “Superiority of azacitidine over conventional care regimens was previously shown in AML with 20% to 30% blasts.(216) Up to 6 courses may be needed to observe maximal responsewith azacitidine or decitabine, although patients without response after 3 courses are unlikely to respond with further therapy”
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. (2015, background): “Azacitidine was shown to prolong OS compared with conventional care regimens (CCRs) in the subset of older patients with 20% to 30% BM blasts in the phase 3 AZA-001 trial.(13) Similarly, azacitidine treatment has been associated with an encouraging median OS of approximately 9 to 10 months in patien”